Gold prices near 3-week lows as stronger dollar, trade progress weigh
GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm specializing in RNA interference (RNAi) therapies, has released promising preclinical data on its candidate SIL204’s efficacy in combating KRAS-driven cancers. The study showcased a significant inhibition of tumor cell proliferation in pancreatic, colorectal, and lung cancer cell lines. With a current market capitalization of just $8.11 million, InvestingPro data shows the company faces significant financial challenges, including rapid cash burn and weak profit margins.
The research indicated that SIL204, which utilizes a lipid-conjugated delivery system, could inhibit the growth and metabolic activity of cancer cells with the KRAS G12D mutation. Notably, in GP2D human colorectal cancer cells, an inhibition rate of approximately 90% was observed.
Following these findings, Silexion plans to conduct further preclinical studies focusing on lung cancer cell lines to expand on the data. The company’s CEO, Ilan Hadar, emphasized the potential of SIL204 to address multiple high-need KRAS-driven cancers.
The Chief Scientific Officer, Mitchell Shirvan, Ph.D., highlighted the drug’s ability to silence the KRAS gene, which is a fundamental driver of these aggressive cancers. This could potentially offer an alternative to conventional treatments that often face resistance issues.
KRAS mutations are prevalent in a significant portion of human cancers, including approximately 90% of pancreatic cancers, around 45% of colorectal cancers, and about 35% of non-squamous non-small-cell lung cancers. The global market for treatments in these areas already exceeds $30 billion annually, underscoring the importance of developing effective therapies. Despite the massive market opportunity, Silexion’s stock has declined by 99% over the past year, though InvestingPro analysis suggests the stock may be undervalued at current levels. Subscribers can access 6 additional key insights about SLXN’s financial health and market position.
Silexion’s advancement of SIL204 follows its first-generation product, LODER™, which showed positive results in a Phase 2 trial for non-resectable pancreatic cancer. The company continues to focus on improving outcomes for patients with challenging cancers through innovative RNAi therapies. However, InvestingPro data reveals concerning financial metrics, including a current ratio of 0.64 and negative EBITDA of $12.55 million, highlighting the challenges ahead. The company’s next earnings report is due in 15 days, which could provide crucial updates on its financial position.
This report is based on a press release statement by Silexion Therapeutics Corp. It should be noted that forward-looking statements involve risks and uncertainties, and the actual results may differ from those projected. The company has cautioned against placing undue reliance on these statements, which only reflect beliefs as of the date made.
In other recent news, Silexion Therapeutics Corp. announced a strategic collaboration with Catalent to develop its siRNA candidate, SIL204, aimed at treating KRAS-driven cancers. This partnership will focus on optimizing SIL204’s formulations for both systemic and intratumoral delivery, following promising preclinical results. Additionally, Silexion has expanded its development plan for SIL204 with a dual-route strategy to target primary tumors and metastases, particularly in pancreatic cancer. The company plans to conduct further studies throughout 2025, with regulatory submissions expected in late 2025 and early 2026. In another development, Silexion reached an agreement to retire a convertible promissory note held by EarlyBirdCapital, Inc. The deal involved a $400,000 cash payment and the issuance of 277,777 ordinary shares. This financial move is part of Silexion’s ongoing efforts to manage its financial obligations. These recent developments reflect Silexion’s commitment to advancing its cancer therapies and maintaining robust financial management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.